Research Article

The Effect of Chronic Kidney Disease Treatment on The Quality of Life Assessed by Using SF-36 in Turkey: A Systematic Review

Volume: 13 Number: 1 January 1, 2022
EN

The Effect of Chronic Kidney Disease Treatment on The Quality of Life Assessed by Using SF-36 in Turkey: A Systematic Review

Abstract

Objective: Quality of life assessment of chronic kidney patients is becoming increasingly common in both research and clinical practice. One of the most commonly used tools for quality of life measurement is the SF-36. The aim of the study is to make a systematic analysis of researches on adult patients receiving hemodialysis treatment and measures the quality of life using the SF-36 in Turkey. Materials and Methods: Researches in the literature on quality of life were determined by using data sources. The studies that did not meet the criteria determined within the scope of the study were eliminated and in total 28 studies conducted between 2013-2019 including 3028 patient samples were reached. Results: The mean age of the samples was 53.06(±5.62) years; the mean duration of hemodialysis treatment was 4.97 years and the mean of female patients was 44.64%. Researches were mostly applied in Marmara Region. 40% of the studies examined the effects of anxiety and depression and 11% of the studies examined the effects of self-care and coping skills on quality of life. When the means of the SF-36 were examined, it was found that the lowest subdimension averages were “Role Physical” and “General Health”. In addition, the patients' physical quality of life was found to be less than the mental dimension. Conclusion: In general, when the findings are evaluated, it is seen that chronic kidney patients have a greatly decreased quality of life. With this research findings, a general view has been put forward. Thus, it is thought that it will guide researchers about chronic kidney disease management.

Keywords

References

  1. 1. Türkiye Ulusal Hastalık Yükü Çalışması. Ulusal Hastalık Yükü Çalışması. Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü, 2013
  2. 2. World Health Organization. Noncommunicable diseases. 2017. Available from: http://www.who.int /media centre/factsheets/fs355/en/.
  3. 3. National Kidney Foundation. About chronic kidney disease. 2013. Available from: http://www.kidney.org/kidneydisease/aboutckd.cfm.
  4. 4. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives–a position statement from Kidney Disease Improving Global Outcomes. Kidney International 2007; 72: 247-259.
  5. 5. Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V. Chronic kidney disease and the global NCDs agenda. BMJ 2017; 2: 1-4.
  6. 6. Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3: 1-150.
  7. 7. Maor Y, King M, Olmer L, Mozes BA. comparison of three measures: the time trade-off technique, global health-related quality of life and the SF-36 in dialysis patients. Journal of clinical epidemiology 2001; 54: 565-570.
  8. 8. Fayers PM. Machin D. Quality of life: the assessment, analysis and reporting of patient-reported outcomes. UK: John Wiley & Sons; 2016.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

January 1, 2022

Submission Date

January 18, 2021

Acceptance Date

October 31, 2021

Published in Issue

Year 2022 Volume: 13 Number: 1

EndNote
Bayın Donar G (January 1, 2022) The Effect of Chronic Kidney Disease Treatment on The Quality of Life Assessed by Using SF-36 in Turkey: A Systematic Review. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 13 1 175–180.